Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Galenica to acquire Aspreva

Galenica (SWX:GALN) will acquire Aspreva (TSX:ASV; ASPV) for US$26 per share or about US$915 million in cash. The deal is a 16% premium

Read the full 233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE